Winfield v. Eloxx Pharmaceuticals, Inc.

District Court, D. Delaware·Decided March 23, 2020·No. 1:19-cv-00447·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

JOHN WINFIELD, Plaintiff, V. Civil Action No. 19-447-RGA ELOXX PHARMACEUTICALS, INC., DAVID RECTOR, JAMES SCHMIDT, BARRY HONIG, and DOES 1-10, inclusive, Defendants.

William R. Firth, I, CKR LAW LLP, Wilmington, DE; Michael James Maloney, FELICELLO LAW P.C., New York, NY, Attorneys for Plaintiff.

Kevin M. Gallagher, RICHARDS, LAYTON & FINGER, P.A., Wilmington, DE; and Luke T. Cadigan, Elizabeth M. Wright, and Gemma Seidita, COOLEY LLP, Boston, MA, Attorneys for Defendants Eloxx Pharmaceuticals, Inc., David Rector, and James Schmidt. David S. Eagle and Sean M. Brennecke, KLEHR HARRISON HARVEY BRANZBURG LLP, Wilmington, DE; and Robert D. Weber, SHEPPARD, MULLIN, RICHTER & HAMPTON LLP, Los Angeles, CA, Attorneys for Defendant Barry Honig.

March 23, 2020

/s/ Richard G. Andrews ANDREWS, UNITED STATES DISTRICT JUDGE: Before me is the Report & Recommendation (“Report”) of a United States Magistrate Judge. (D.I. 27). It addresses (1) the motion to dismiss for failure to state a claim under Rule 12(b)(6), filed by Defendants Eloxx Pharmaceuticals, Inc., David Rector, and James Schmidt (D.I. 8); and (2) the motion to dismiss for failure to state a claim under Rule 12(b)(6), filed by Defendant Barry Honig (D.I. 11). Defendants filed objections to the Report. (D.I. 28, 29). Plaintiff responded to Defendants’ objections. (D.I. 31). The Magistrate Judge’s Report is comprehensive, and I will adopt the factual findings and legal conclusions in the Report except as indicated. I do not separately recite any of them except as I think necessary to explain my decision. I. LEGAL STANDARD Magistrate Judges have the authority to make recommendations as to the appropriate resolution of a motion to dismiss pursuant to 28 U.S.C. § 636(b)(1)(B). In the event of an objection, this Court reviews the objected-to determinations de novo. When reviewing a motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6), the Court must accept the complaint’s factual allegations as true. See Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555-56 (2007). Rule 8(a) requires “a short and plain statement of the claim showing that the pleader is entitled to relief.” Jd. at 555. The factual allegations do not have to be detailed, but they must provide more than labels, conclusions, or a “formulaic recitation” of the claim elements. /d. (“Factual assumptions must be enough to raise a right to relief above the speculative level ... on the assumption that the allegations in the complaint are true (even if doubtful in fact).”). There must also be sufficient factual matter to state a facially plausible claim to relief. Ashcroft v. Igbal, 556 U.S. 662, 678 (2009). The facial plausibility

standard is satisfied when the complaint’s factual content “allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Jd. (“Where a complaint pleads facts that are merely consistent with a defendant’s liability, it stops short of the line between possibility and plausibility of entitlement to relief.” (internal quotation marks omitted)). Il. DISCUSSION a. Breach of Contract With regard to the breach of contract claim, which is against Eloxx, Defendants’ first objection is to the Magistrate Judge’s finding that the interpretation of “consent” and “amendment,” as used in Section 2.2(g) of the Agreement, raises an issue inappropriate for resolution on a motion to dismiss. (D.I. 28 at 2). Defendants’ second objection is that the Complaint does not sufficiently allege that the Company breached a contractual obligation set forth in the four corners of the contract. (/d. at 3). Defendants’ third objection is to the Magistrate Judge’s finding of a factual dispute about the term “closing.” (/d.). The Magistrate Judge offered a reasonable interpretation of the contract at issue, which Defendants contest. (D.I. 27 at 8). I agree with the determination of the plausibility of Plaintiffs position, under the terms of the Agreement, that the closing did not occur until Plaintiff tendered his stock certificate. Indeed, the relevant language of the Agreement appears to create an obligation that survives the date of closing. Since the parties’ dispute appears to focus on the scope of Section 2.2(g) of the Agreement, and I agree that Plaintiff's interpretation is plausible, I agree with the Magistrate Judge that the issues of contract interpretation raised by Defendants cannot be resolved against Plaintiff on a motion to dismiss.

Thus, I overrule Defendants’ objections and accept the recommendation to deny Defendants’ motion as to the breach of contract claim. b. Breach of the Implied Covenant of Good Faith and Fair Dealing Plaintiff does not adequately identify an implied contractual obligation and Plaintiffs cause of action for breach of the implied covenant is based on the same underlying facts as the cause of action for breach of the express terms of the Agreement. The Magistrate Judge so ruled, and there is no objection. I agree with the Report’s recommendation and will grant the motion to dismiss Plaintiff's fifth cause of action for breach of the implied covenant of good faith and fair dealing. c. Securities Fraud Under Section 10(b) and Rule 10b-5 i. Misstatement or omission Defendants contend that the Report erroneously recommends that the Complaint adequately pleads the falsity of Defendants’ statements. (D.I. 27 at 15; citing D.I. 1 at § 24). The Report states, ‘The timing of Mr. Honig’s conversion only a few weeks after Plaintiff's conversion gives rise to a strong inference that Defendants’ statements regarding the most favorable conversion price were false at the time they were made.” (/d.). Defendants state that this inference is based on the premise that the conversion did not occur until Plaintiff tendered his certificate and argue that instead, the conversion was complete as of the Closing on February 15, 2017. (D.I. 28 at 5). As described at length in the Report, the facts alleged paint a different picture, one in which Defendants Rector and Honig failed to disclose or offer a lower conversion price to Plaintiff during a period in which Plaintiff's preferred shares had not yet been exchanged for

common shares. (D.I. 27 at 15-16). Thus, I overrule Defendants’ objections as they relate to the involvement of Defendants Rector and Honig. With regard to Defendant Schmidt, the Complaint states only that he “told Plaintiff that the other holder of the remaining series A preferred stock had reached an agreement and that those shares would be converted at the same price as in Plaintiff's agreement,” before asking Plaintiff to tender his certificate. (D.I. 1 at § 21). Plaintiff asserts that Defendant Schmidt’s position as interim CFO, his knowledge of the Agreement provided to Plaintiff, his communication to Plaintiff, and his role in controlling the conversion prices offered to investors create a plausible inference that his involvement in the alleged misrepresentation was knowing or intentional. (D.I. 31 at 8-9). I do not find the facts alleged to be pleaded with sufficient particularity against Defendant Schmidt. It is possible that Defendant Schmidt conveyed the described message to Plaintiff based on what Defendants Rector or Honig told him, for example. Plaintiff makes no allegation that Defendant Schmidt knew, at the time that he spoke with Plaintiff, that nearly two months later Defendant Honig would have a better deal.

Free access — add to your briefcase to read the full text and ask questions with AI

Winfield v. Eloxx Pharmaceuticals, Inc., (D. Del. 2020).

Winfield v. Eloxx Pharmaceuticals, Inc. (Winfield v. Eloxx Pharmaceuticals, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)